Exhibit 10.19

 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***],
HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE
COMPETITIVE HARM IF PUBLICLY DISCLOSED.

 

AMENDMENT NO. 1 TO THE COLLABORATION AND LICENSE AGREEMENT

This Amendment No. 1 to the Collaboration and License Agreement (“Amendment”) is
made and entered into, effective as of December 17, 2019 (“Amendment Effective
Date”), by and between Vir Biotechnology, Inc., a Delaware corporation with
offices at with an office at 499 Illinois Street, San Francisco, California
94158 (“Vir”), and Alnylam Pharmaceuticals, Inc., a Delaware corporation located
at 300 Third Street, Cambridge, Massachusetts 02142 (“Alnylam”). Each of Vir and
Alnylam are referred to in this Amendment as a “Party” and together, the
“Parties”.

Background

WHEREAS, the Parties have entered into that certain Collaboration and License
Agreement effective as of October 16, 2017 (as amended by Letter Agreement dated
November 13, 2018, the “Collaboration Agreement”) pursuant to which the Parties
entered into a collaboration to develop and commercialize certain compounds and
products based on Alnylam’s RNAi technology, in connection with Hepatitis B and
other infectious diseases;

WHEREAS, pursuant to Section 3.1(b) of the Collaboration Agreement Vir has
selected its four (4) ID Collaboration Targets and the Parties desire to update
Schedule D to the Collaboration Agreement accordingly;

WHEREAS, the Parties also desire to amend certain provisions of the
Collaboration Agreement applicable to Alnylam’s funding of the POC Study for the
initial HBV Licensed Product and related milestone payment triggers;

WHEREAS, concurrent with the execution of the Collaboration Agreement, the
Parties also entered into a Common Stock Issuance Agreement (referred to as the
“Stock Purchase Agreement”), and the Parties also desire to amend the Stock
Purchase Agreement to align a milestone payment trigger contained therein with
the changes being made pursuant to this Amendment; and

WHEREAS, Section 14.4 of the Collaboration Agreement provides that the
Collaboration Agreement may only be modified by a written instrument duly
executed by an authorized representative of each Party.

NOW, THEREFORE, the Parties desire, for good and valuable consideration, the
receipt and sufficiency of which is hereby acknowledged, to amend the
Collaboration Agreement as set forth in this Amendment.

Article 1
DEFINITIONS

1.1Capitalized Terms. Capitalized terms used in this Amendment shall have the
meanings set forth in the Collaboration Agreement unless otherwise defined and
set forth in this Amendment. Except as expressly modified by this Amendment, the
remainder of the Collaboration Agreement shall remain in force in accordance
with its terms and without any modification.

 

--------------------------------------------------------------------------------

 

Article 2
AMENDMENTS

2.1Addition of New Section 1.1.99A and Schedule 1.1.99A. Article 1 of the
Collaboration Agreement is hereby amended by adding new Section 1.1.99A and
inserting a new definition immediately following Section 1.1.99, as follows:

1.1.99A“Initial HBV02 Study” shall mean the phase I/II Clinical Study of
ALN-HBV02 [***], as further described in the attached Schedule 1.1.99A.

2.2Amendment of Section 1.1.3. Section 1.1.3 of the Collaboration Agreement is
hereby amended in its entirety, as follows:

1.1.3“Achievement of Human POC” shall mean (i) solely with respect to the
Initial HBV02 Study [***] the Parties reasonably determine that the results from
such POC Study support the continuation of preparation and conduct of a Phase II
Study and that [***] based on the results of such POC Study; [***]; and (ii) for
any POC Study other than the Initial HBV02 Study, that the Parties reasonably
determine that the results from such POC Study support the continuation of
preparation and conduct of a Phase II Study and that [***].  

2.3Amendment of Section 1.1.8. Section 1.1.8 of the Collaboration Agreement is
hereby amended to replace “Additional Funding Activity” with “Additional Funded
Activity”.

2.4Amendment of Section 1.1.48.  Section 1.1.48 of the Collaboration Agreement
is hereby amended in its entirety, as follows:

1.1.148“Completion” shall mean (i) for the Initial HBV02 Study [***]; and, (ii)
for all other Clinical Studies other than the Initial HBV02 Study, with respect
to each such Clinical Study, database lock for such Clinical Study.

2.5Amendment of Section 1.1.132. Section 1.1.132 of the Collaboration Agreement
is hereby amended in its entirety, as follows:

1.1.132“POC Study” shall mean (a) with respect to the HBV Program, the Clinical
Study of ALN-HBV02 to evaluate safety in human volunteers and [***], as further
described in Schedule 1.1.99A [***]; and (b) with respect to an ID Program, a
Clinical Study of an ID Licensed Product Directed to the ID Collaboration Target
in such ID Program that is designed to demonstrate human safety and [***], as
further described in the applicable ID Development Plan.

2.6Amendment of Section 1.1.164. Section 1.1.164 of the Collaboration Agreement
is hereby amended in its entirety, as follows:

1.1.164“Stock Purchase Agreement” shall mean that certain Common Stock Issuance
Agreement between the Parties dated as of the Effective Date and attached hereto
as Schedule G, as such agreement is amended from time to time.

2.7Amendment of Schedule D (ID Targets, Reserved Targets and ID Collaboration
Targets). Schedule D (ID Targets, Reserved Targets and ID Collaboration Targets)
of the Collaboration Agreement is hereby amended in its entirety by replacing it
with the Schedule D attached to this Amendment. Notwithstanding anything to the
contrary in the Collaboration Agreement, including Section 6.1(b) and Section
10.5(a)(i), the Parties agree that Alnylam shall retain the right to [***].

 

 

--------------------------------------------------------------------------------

 

Article 3
MISCELLANEOUS

3.1No Waiver. Nothing in this Amendment is intended to operate as a waiver of
any claims either Party may have against the other Party arising prior to the
date of this Amendment, including any claims arising prior to the date of this
Amendment with respect to the performance of the Parties under the Collaboration
Agreement. Any delay in enforcing a party’s rights under this Amendment or the
Collaboration Agreement, or any waiver as to a particular default or other
matter, will not constitute a waiver of such party’s rights to the future
enforcement of its rights under this Amendment or the Collaboration Agreement,
except with respect to an express written waiver relating to a particular matter
for a particular period of time signed by an authorized representative of the
waiving Party, as applicable.

3.2Miscellaneous. This Amendment shall be governed by and interpreted in
accordance with the law of the State of New York, U.S.A., without reference to
any principles of conflicts of laws to the contrary. The United Nations
Convention on Contracts for the International Sale of Goods shall not apply to
the transactions contemplated by this Amendment. Except as specifically amended
by this Amendment, the terms and conditions of the Collaboration Agreement shall
remain in full force and effect. This Amendment may be executed in two or more
counterparts, each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument. Signatures transmitted by
PDF shall be treated as original signatures. Except to the extent expressly
provided herein, the Collaboration Agreement, as amended by this Amendment,
together with the Commitment Letter between the Parties entered into on the
Commitment Letter Date and the Stock Purchase Agreement, including all
appendices, exhibits and schedules to each of the foregoing, constitute the
entire agreement between the Parties relating to the subject matter of the
Collaboration Agreement and supersedes all previous oral and written
communications, including all previous agreements, between the Parties.

[Remainder of Page Intentionally Left Blank]

 

 

 

 

--------------------------------------------------------------------------------

 

IN WITNESS WHEREOF, on the Amendment Effective Date Vir and Alnylam have caused
this Amendment to be duly executed by their authorized representatives.

 

 

Vir Biotechnology, Inc.

 

 

By:

/s/ George Scangos

 

 

Name:

George Scangos

 

 

Title:

President and Chief Executive Officer

 

 

Alnylam Pharmaceuticals, Inc.

 

 

By:

/s/ John Maraganore

 

 

Name:

John Maraganore

 

 

Title:

Chief Executive Officer

 

 

 

--------------------------------------------------------------------------------

 

SCHEDULE 1.1.99A

INITIAL HBV02 STUDY

 

[***]

 

 

 

--------------------------------------------------------------------------------

 

SCHEDULE D

ID Targets, RESERVED tARGETS and id collaboration targets

[***]